Compare AbbVie Inc (ABBV) vs Global X MSCI Argentina ETF (ARGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Global X MSCI Argentina ETF — how do they compare? AbbVie Inc trades at $253.58 (market cap $449.91B), while Global X MSCI Argentina ETF trades at $92.62. The key difference: AbbVie Inc pays a 2.72% dividend while Global X MSCI Argentina ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Global X MSCI Argentina ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | ARGT | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $102.94 |
52-Week Low | $184.85 | $67.55 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
ARGT trades at $93.99, up 2.78% today, but technical indicators signal a bearish trend with moving averages showing sell pressure. The stock is near resistance at $94, with support at $90. Recent news highlights institutional interest from Stanley Druckenmiller and analyst upgrades citing Argentina's economic reforms and potential valuation upside.
Outlook remains mixed; bullish sentiment from analysts points to a 28% upside if Argentina's turnaround continues, but risks include political volatility and concentrated holdings. The stock offers speculative growth potential amid high macroeconomic uncertainty, requiring careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Global X MSCI Argentina ETF
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →
